Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma

被引:33
作者
Luo, Jizhuang [1 ]
Wang, Rui [1 ]
Han, Baohui [2 ]
Zhang, Jie [3 ]
Zhao, Heng [1 ]
Fang, Wentao [1 ]
Luo, Qingquan [4 ]
Yang, Jun [1 ]
Yang, Yunhai [1 ]
Zhu, Lei [3 ]
Chen, Tianxiang [1 ]
Cheng, Xinghua [5 ]
Huang, Qingyuan [1 ]
Wang, Yiyang [1 ]
Zheng, Jiajie [1 ]
Chen, Haiquan [1 ,5 ,6 ,7 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pathol, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Shanghai Lung Tumor Clin Ctr, Shanghai, Peoples R China
[5] Fudan Univ, Shanghai Canc Ctr, Dept Thorac Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China
[6] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China
[7] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Invasive mucinous adenocarcinoma; Stage I; NSCLC; Classification; Adjuvant chemotherapy; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; ADJUVANT CHEMOTHERAPY; INTERNATIONAL-ASSOCIATION; KRAS MUTATION; CLASSIFICATION; SURVIVAL; SUBTYPE; PREDICTOR; RECURRENCE;
D O I
10.1007/s00432-016-2201-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The correlations between histological, clinical features and prognosis of stage I invasive mucinous adenocarcinoma (IMA) have not been thoroughly studied for its rare incidence. This study aimed to compare the prognosis among IMA with different percentage of mucinous component and the effect of adjuvant chemotherapy on IMA patients. A total of 145 stage I IMA and 3536 invasive nonmucinous adenocarcinoma patients with R0 resection were included. Based on the percentage of mucinous pattern presented in tumor, IMA were classified into two subgroups: pure mucinous (> 90 % invasive mucinous pattern) and mixed mucinous/nonmucinous (a parts per thousand yen10 % of each histologic component). Invasive nonmucinous adenocarcinomas were classified into three subgroups: lepidic (LEP), acinar/papillary (ACN/PAP) and solid/micropapillary (SOL/MIP). Disease-free survival (DFS) and overall survival (OS) were assessed and compared among IMA and invasive nonmucinous patients. For IMA patients, DFS (p = 0.003) was worse for mixed mucinous/nonmucinous compared with pure mucinous subgroup, OS (p = 0.514) was not prognostically different between two groups. There were no significant difference for DFS (p = 0.428) and OS (p = 0.232) between IMA and invasive nonmucinous adenocarcinoma. However, statistical significance were seen for DFS (p < 0.001) and OS (p < 0.001) between 5 major histological subgroups: LEP and pure IMA showed excellent prognosis, mixed mucinous/nonmucinous IMA and SOL/MIP subtypes presented the worst prognosis. No significant survival benefit from adjuvant chemotherapy for IMA patients. Mixed mucinous/nonmucinous IMA had a worse DFS compared with pure mucinous. Early stage IMA could not benefit from adjuvant chemotherapy.
引用
收藏
页码:1837 / 1845
页数:9
相关论文
共 26 条
[1]
Validation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients with Early Stage Lung Adenocarcinoma [J].
Bueno, Raphael ;
Hughes, Elisha ;
Wagner, Susanne ;
Gutin, Alexander S. ;
Lanchbury, Jerry S. ;
Zheng, Yifan ;
Archer, Michael A. ;
Gustafson, Corinne ;
Jones, Joshua T. ;
Rushton, Kristen ;
Saam, Jennifer ;
Kim, Edward ;
Barberis, Massimo ;
Wistuba, Ignacio ;
Wenstrup, Richard J. ;
Wallace, William A. ;
Hartman, Anne-Renee ;
Harrison, David J. .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) :67-73
[2]
Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma [J].
Cai, Deng ;
Li, Hang ;
Wang, Rui ;
Li, Yuan ;
Pan, Yunjian ;
Hu, Haichuan ;
Zhang, Yang ;
Gong, Ranxia ;
Pan, Bin ;
Sun, Yihua ;
Chen, Haiquan .
ONCOTARGETS AND THERAPY, 2014, 7 :2127-2132
[3]
Adjuvant chemotherapy in stage IB non-small cell lung carcinoma: A survival analysis [J].
Coutinho, D. ;
Goncalves, A. ;
Antunes, A. ;
Campainha, S. ;
Miranda, J. ;
Barroso, A. .
REVISTA PORTUGUESA DE PNEUMOLOGIA, 2016, 22 (02) :123-125
[4]
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].
Eberhard, DA ;
Johnson, BE ;
Amler, LC ;
Goddard, AD ;
Heldens, SL ;
Herbst, RS ;
Ince, WL ;
Jänne, PA ;
Januario, T ;
Johnson, DH ;
Klein, P ;
Miller, VA ;
Ostland, MA ;
Ramies, DA ;
Sebisanovic, D ;
Stinson, JA ;
Zhang, YR ;
Seshagiri, S ;
Hillan, KJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909
[5]
Non-Small Cell Lung Cancer, Version 6.2015 Featured Updates to the NCCN Guidelines [J].
Ettinger, David S. ;
Wood, Douglas E. ;
Akerley, Wallace ;
Bazhenova, Lyudmila A. ;
Borghaei, Hossein ;
Camidge, David Ross ;
Cheney, Richard T. ;
Chirieac, Lucian R. ;
D'Amico, Thomas A. ;
Demmy, Todd L. ;
Dilling, Thomas J. ;
Dobelbower, M. Chris ;
Govindan, Ramaswamy ;
Grannis, Frederic W., Jr. ;
Horn, Leora ;
Jahan, Thierry M. ;
Komaki, Ritsuko ;
Krug, Lee M. ;
Lackner, Rudy P. ;
Lanuti, Michael ;
Lilenbaum, Rogerio ;
Lin, Jules ;
Loo, Billy W., Jr. ;
Martins, Renato ;
Otterson, Gregory A. ;
Patel, Jyoti D. ;
Pisters, Katherine M. ;
Reckamp, Karen ;
Riely, Gregory J. ;
Rohren, Eric ;
Schild, Steven E. ;
Shapiro, Theresa A. ;
Swanson, Scott J. ;
Tauer, Kurt ;
Yang, Stephen C. ;
Gregory, Kristina ;
Hughes, Miranda .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (05) :515-524
[6]
The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J].
Goldstraw, Peter ;
Crowley, John ;
Chansky, Kari ;
Giroux, Dorothy J. ;
Groome, Patti A. ;
Rami-Porta, Ramon ;
Postmus, Pieter E. ;
Rusch, Valerie ;
Sobin, Leslie .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :706-714
[7]
Frequency of EGFR and KRAS Mutations in Japanese Patients with Lung Adenocarcinoma with Features of the Mucinous Subtype of Bronchioloalveolar Carcinoma [J].
Hata, Akito ;
Katakami, Nobuyuki ;
Fujita, Shiro ;
Kaji, Reiko ;
Imai, Yukihiro ;
Takahashi, Yutaka ;
Nishimura, Takashi ;
Tomii, Keisuke ;
Ishihara, Kyosuke .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) :1197-1200
[8]
Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer [J].
He, Jiaxi ;
Shen, Jianfei ;
Yang, Chenglin ;
Jiang, Long ;
Liang, Wenhua ;
Shi, Xiaoshun ;
Xu, Xin ;
He, Jianxing .
MEDICINE, 2015, 94 (22) :e903
[9]
Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma [J].
Hung, Jung-Jyh ;
Wu, Yu-Chung ;
Chou, Teh-Ying ;
Jeng, Wen-Juei ;
Yeh, Yi-Chen ;
Hsu, Wen-Hu .
ANNALS OF THORACIC SURGERY, 2016, 101 (04) :1346-1353
[10]
Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation [J].
Ichinokawa, Hideomi ;
Ishii, Genichiro ;
Nagai, Kanji ;
Kawase, Akikazu ;
Yoshida, Junji ;
Nishimura, Mitsuyo ;
Hishida, Tomoyuki ;
Ogasawara, Naomi ;
Tsuchihara, Katsuya ;
Ochiai, Atsushi .
HUMAN PATHOLOGY, 2013, 44 (12) :2636-2642